We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.
View, monitor and analyze all your compliance data in one place.
Multichannel solution to better manage consent, disputes and pre-disclosure review.
Market and competitor intelligence at your fingertips.
What spend are you going to report under Sunshine Payments or EFPIA? Do you know what is in your data?
What will a journalist conclude when they access your public spend records? What will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?
Let qordata Compliance Insights give you visibility into your own spend. It’s the kind of visibility the CMS/DOJ world wish for.
The latest Pharmaceutical Compliance, Transparency and Analytics insights from around the world, now at your fingertips. Get expert solutions to your specific Pharma Spend Issues.SIGN UP AS AN EXPERT
Efficiency and Foresight: The qordata Advantage For Zimmer Biomet
For Zimmer Biomet, Compliance Insights, a dedicated CMS Open Payments Solution, was an affirmative response to both. Within a short period, Zimmer Biomet recorded 50% cost reduction and a corresponding error rate reduction. It achieved quantifiable savings in time, efficiency, and gained better insights.DOWNLOAD
Helping thousands of people and companies communicate and work better.
qordata Releases Open Payments Data 2016
Princeton, New Jersey: qordata has released Open Payments Data 2016 less than 24 hours after the publication of 11.96 million financial transactions, (US $ value 8.18 billion) on the CMS Website.READ FULL STORY
Thought Leadership —Transparency, Insights And Disclosure
Even the best efforts at pharmaceutical compliance will fail unless the power of analytics is fully harnessed. As qordata prepares companies for their CMS spend submission this year, it continues to discover some astounding outliers in reports medical drug and device companies submitted to the CMS in previous years. These data oversights will earn up to $1.15 million in penalties from the CMS per company. The consistency with which these records have been entered since 2014 can only suggest three things. Pharmaceutical companies either: • Don’t know the seriousness of the issue, • Don’t have enough time for a spend review or • Need help with their spend reporting process CMPs Not Serious Enough? When it comes to Big Pharma […]
Data crunching, monitoring, risk management—traditionally, we have never seen these activities form part of what is the glamorous realm of the brand manager’s toolkit. But—as regulators strive to bring transparency and distributive justice to the pharmaceutical industry, best compliance practices may actually be inching their way into active branding. Perception Reality Gap: “Marketing is the war of perceptions,” is a familiar truism in business textbooks. It’s something marketing professionals have always known, frequently exploited, and increasingly—fallen victim to, themselves too. As access to data gets easier and quicker, the risk of falling victim to one’s own (mis)-perceptions is magnified manifold. ‘Gut instincts’ are only 50% accurate, and going by them, or a superficial, irregular presentation of sales figures gives brand […]
February might prove to be a definitive month for CMS, as it proposes changes to its Medicare Health and Drug Programs, effective 2019. The changes are predicted to make Medicare Advantage more flexible, providing beneficiaries with more options and benefits. Motivating these changes is CMS’ goal of fighting the opioid crisis by revitalizing the doctor-patient communication/relationship. What’s Set To Change Senior citizens will be able to enjoy a wider range of options, and lowered payments for premiums as part of their Medicare Health/Drug Plans. The CMS has widened the definition of supplemental benefits to include assistive devices, portable wheelchair ramps, non-skilled in-home supports and others, a departure from its previous definition of supplemental benefit, which limited items to non-daily maintenance. […]